Local pediatric doctor honored for study featuring Isomark technology.

Home / Isomark News / Local pediatric doctor honored for study featuring Isomark technology.

FOR IMMEDIATE RELEASE (October 12, 2012)
Contact: Dave Kruse, interim-CEO, Isomark, LLC at dave.kruse@isomark.com

 

Local Pediatric Doctor Honored For Landmark Study Featuring Isomark Technology

Madison, WI – Isomark, LLC, a medical device technology company focused on early detection of life-threatening infections, announced today that UW-Madison pediatric critical-care physician Juan P. Boriosi, M.D., was honored at the 2012 Midwest Society for Pediatric Research Annual Meeting.  Dr. Boriosi’s work demonstrates the usefulness of Isomark’s breath biomarker for early detection of sepsis, a severe infection also known as blood poisoning.

Dr. Boriosi received the Sutherland Award for the outstanding abstract presentation by a junior faculty member.  His presentation detailed the results of his study, which was conducted to test the effectiveness of Isomark’s early detection technology on diagnosing sepsis.  Sepsis is one of the leading causes of death in the U.S. and early detection can significantly reduce mortality rates and the costs associated with treatment of the infection.  During the study, Isomark’s device detected infection 48 hours before laboratory confirmation.

The study, conducted in the pediatric intensive care unit at American Family Children’s Hospital in Madison, Wis., used Isomark’s device to measure an exhaled biomarker of sepsis in 17 mechanically ventilated pediatric patients every eight hours over a 72-hour period. The results indicate that the Isomark breath biomarker was a leading indicator of sepsis in those patients that developed infection during the study.

“Early detection is extremely important for critical care patients who contract infections,” said Dr. Boriosi, who works at American Family Children’s and is also a faculty member of the University of Wisconsin School of Medicine and Public Health in Madison.

Sepsis occurs in one to two percent of all hospitalizations and occurs in as many as 25 percent of ICU beds. In 2010 it was the 11th overall leading cause of death in the United States, according to data from the U.S. Centers for Disease Control and Prevention.

“This is a pivotal milestone for us,” noted Isomark Chief Scientific Officer Dan Butz, Ph.D. “Bringing a concept medical device out of the lab and into the hands of the physicians to potentially save human lives is extremely gratifying.”

Isomark co-founder Mark Cook Ph.D., added, “Our next steps are to initiate more clinical trials to get Isomark’s medical device 510(k) approved as quickly as possible so every trauma doctor like Dr.Boriosi can passionately fight sepsis alongside us.”

 

About Isomark:

Madison-based Isomark, LLC was founded in 2007 using technology developed at the University of Wisconsin – Madison and patented by Wisconsin Alumni Research Foundation (WARF). The company’s mission is to provide breath based near-real-time monitoring technology for the detection of life-threatening infections, allowing faster and more accurate diagnosis, with the goal of improving patient outcomes. For more information, please visit www.isomark.com.

 

 

###